Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV
Antimicrobial Agents and Chemotherapy · 05.08.2026 · 70 (8)
DOI: 10.1128/aac.00592-26 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.08.2026. Verfasst von Jennie van Dyk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Anti-HIV Agents, Atazanavir Sulfate, HIV Infections, Ritonavir. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, European and Developing Countries Clinical Trials Partnership, NIHR Global Health Research Professorship.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Ritonavir-boosted atazanavir (atazanavir/r) is an effective once-daily option for pediatric subsequent-line antiretroviral therapy when used with two nucleoside reverse transcriptase inhibitors (NRTIs). Tuberculosis co-treatment complicates its use because rifampicin markedly induces atazanavir/r clearance. Although twice-daily atazanavir/r can overcome this interaction in adults, data in children are lacking. We aimed to characterize atazanavir population pharmacokinetics in children with HIV and simulate the effect of rifampicin co-treatment. Atazanavir concentration-time data in African children with HIV from CHAPAS-4 (ISRCTN22964075) and VirTUAL (NCT03923231) were analyzed by nonlinear mixed-effect modeling. We investigated the effect of weight, age, atazanavir formulation, ritonavir dose, and NRTI backbone (tenofovir alafenamide [TAF]-emtricitabine, abacavir-lamivudine, or zidovudine-lamivudine). Simulations were performed across weight bands to evaluate atazanavir/r exposures under standard conditions and, using adult-derived induction effects, predict exposures and possible dosing regimens during rifampicin co-treatment. Seventy children were included, with a median (range) age of 10.9 (3.2–17.7) years and weight of 29 (15–85) kg. A two-compartment model with sequential zero- and first-order absorption best described atazanavir disposition. The estimated typical value of atazanavir clearance was 4.8 L/h for a 27-kg individual. Atazanavir pharmacokinetics in children were unaffected by the NRTI backbone. Once-daily atazanavir/r with current dosing guidelines achieved adequate exposures across weight bands. When simulating pharmacokinetics during rifampicin co-treatment, twice-daily atazanavir/r is expected to restore exposures to levels comparable to once-daily dosing without rifampicin. These findings provide a framework for future clinical evaluation in children with HIV and tuberculosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
- Department of Women's and Children's Health, University of Liverpool, Liverpool, United Kingdom.
- Joint Clinical Research Centre, Lubowa, Uganda.
- Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
- HIV and Infectious Diseases Unit, South African Medical Research Council, Cape Town, South Africa.
ORCID-Profile: Jennie van Dyk, Catriona Waitt, Lubbe Wiesner, Helen M McIlleron, Paolo Denti, Roeland E Wasmann
Förderung
- Medical Research Council
- European and Developing Countries Clinical Trials Partnership
- NIHR Global Health Research Professorship
Zitieren
APA
van Dyk, J., Waitt, C., Mugerwa, H., Wiesner, L., Orrell, C., Bamford, A., Gibb, D. M., McIlleron, H. M., Colbers, A., Burger, D. M., Denti, P., & Wasmann, R. E. (2026). Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV. Antimicrobial Agents and Chemotherapy, 70(8). https://doi.org/10.1128/aac.00592-26
Vancouver
van Dyk J, Waitt C, Mugerwa H, Wiesner L, Orrell C, Bamford A, et al. Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV. Antimicrobial Agents and Chemotherapy. 2026;70(8). doi:10.1128/aac.00592-26
BibTeX
@article{vanDyk2026,
author = {van Dyk, Jennie and Waitt, Catriona and Mugerwa, Henry and Wiesner, Lubbe and Orrell, Catherine and Bamford, Alasdair and Gibb, Diana M and McIlleron, Helen M and Colbers, Angela and Burger, David M and Denti, Paolo and Wasmann, Roeland E},
title = {Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {8},
doi = {10.1128/aac.00592-26}
}
EUVIMED